Long-Term Outcome of Allogeneic Hematopoietic Cell Transplantation for Patients With Mycosis Fungoides and Sézary Syndrome: A European Society for Blood and Marrow Transplantation Lymphoma Working Party Extended Analysis

In 2010, the European Society for Blood and Marrow Transplantation (EBMT) reported an overall survival (OS) of 66% at 1 year and 54% at 3 years after allogeneic hematopoietic cell transplantation (HCT) in patients with advanced-stage mycosis fungoides and Se zary syndrome (MF/SS). Here, we present an extended analysis of this experience, with a median follow-up in survivors of 7 years (longest follow-up: 12 years; interquartile range: 6 to 9 years). The analysis focuses on nonrelapse mortality (NRM), cumulative incidence of relapse/progression, progression-free survival (PFS), OS, and the impact of disease and transplant factors on long-term patient outcome.